跳至主要内容
临床试验/NCT01117649
NCT01117649已完成4 期

Prospective, Controlled, Double-blind, Randomized Multi-centric Study on the Efficacy and Safety of a Target Controlled PVR Therapy With a Hyperoncotic Balanced Hydroxyethyl Starch (HES) Solution Versus an Isooncotic Balanced HES Solution Compared to a Balanced Electrolyte Solution in Elective Surgery

B. Braun Melsungen AG3 个研究点 分布在 1 个国家目标入组 63 人开始时间: 2010年5月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
63
试验地点
3
主要终点
First endpoint: Intraoperatively required amount of HES (10%, 6%) (ml)

研究概览

简要总结

The purpose of this study is to investigate the efficacy of target controlled fluid therapy with a hyper-oncotic balanced HES solution compared to an iso-oncotic HES solution in patients undergoing elective surgery of the pancreatic head. A third group receiving a balanced electrolyte solution (without colloidal volume replacement) will serve as a control for descriptive analysis.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

2

Active Comparator

iso-oncotic colloid

干预措施: HES 6% (Drug)

1

Experimental

hyper-oncotic colloid

干预措施: HES 10% (Drug)

3

Active Comparator

crystalloid

干预措施: balanced electrolyte solution (Drug)

结局指标

主要结局

First endpoint: Intraoperatively required amount of HES (10%, 6%) (ml)

时间窗: up to 8 hours

Goal-directed (stroke volume) plasma volume therapy

Second endpoint: Time until fully on oral (solid) diet (days)

时间窗: up to 15 days

次要结局

  • haemodynamics, arterial blood gas analysis, laboratory data, postoperative nausea and vomiting, adverse events, nursing delirium screening scale, several injury scores(up to 7 days)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (3)

Loading locations...

相似试验